Managers, mothers, mentors, professionals – there are many roles a woman can take on in their life. With that comes everyday challenges in both your professional and personal life, the last thing that should be on your mind is your intimate health. Here at Texas Dermatology, a breakthrough vaginal rejuvenation treatment is now an option for women.
Ever laughed so hard you leaked in the wrong places? You’re not the only one.
Many women will experience urinary incontinence in their lifetime, which can cause physical and emotional distress. In between hormones, menopause, and childbirth, a woman’s body can go through a lot of changes.
- 50% of women suffer from unwanted bladder leakage.
- 46% of women with urinary incontinence say it negatively affected their sexual function.
- 40% of women suffer from sexual dysfunction.
How does it work?
In just one 30-45-minute session, the Viveve Treatment is a nonsurgical treatment that uses radiofrequency to rebuild vaginal tissue which promotes collagen production.
- Treatment is non-surgical.
- Comfortable and safe.
- No anesthesia, no pain, no medication.
Sound too good to be true? It’s not! Clinical studies have shown sustained results 12 months after the treatment.
Women who have the treatment experience noticeable changes. After a few weeks, women experience a decrease in urinary leakage and an increase in vaginal tightness & lubrication. The Viveve treatment also improves sexual sensation.
Mary, a Viveve patient stated, “After having had three children I had a sense of urgency and I did experience some leakage. I came in, had the procedure which took 45 minutes and after that I actually noticed the results immediately.”
Feel the Difference
You can feel the difference too. The Viveve treatment is for any woman who has trouble with urinary continence, sexual dysfunction, or simply wants to feel confident again.
This month take advantage of the Viveve special and save $300 off the treatment! To learn more about the Viveve Treatment, click here or give us a call at 210-245-4050.
Watch our KENS 5 News Segment